RNA therapeutics for heart disease

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• The human genome extensively encodes non-coding RNAs (ncRNAs) with critical regulatory roles in disease.
• Both coding and non-coding RNAs are implicated in the pathogenesis of heart disease.
• RNA-targeting molecules demonstrate significant preclinical efficacy for therapeutic development.

Purpose of the Study:

• To review the biochemical foundations of RNA-based drug design.
• To highlight promising preclinical RNA-based therapeutic candidates for heart disease.
• To discuss challenges and future directions for clinical translation in myocardial disorders.

Main Methods:

• Review of current literature on RNA biology and drug design.
• Analysis of preclinical data for RNA-based therapeutics.
• Discussion of biochemical principles and clinical translation barriers.

Main Results:

• RNA-based drug design leverages the regulatory functions of ncRNAs.
• Several RNA-targeting strategies show promise in preclinical models of heart disease.
• Significant hurdles remain in translating these findings to clinical applications.

Conclusions:

• RNA-based therapeutics represent a novel class of drugs targeting previously undruggable targets.
• Overcoming barriers in RNA drug delivery and stability is crucial for clinical success.
• Future research should focus on advancing RNA-based therapies for myocardial disorders.